

Microbiome Drug Database

Microbiome Drug Database, a live tool, updated on a regular basis depicts, as accurately as possible, the current microbiome pharma landscape.

It is the most comprehensive global database of microbiome biotechs developing pharmaceuticals, consisting of almost 309+ companies and 1350+ active research programs.

Constant Microbiome			Home	Compar -	ies Search	θ	Profile
Total Companies 317	Total Research Programs 1372		Total Funds Raised € 9,531.95 millions		Total Disease Targ 350	ets	
Search Please type any term, at list 3 letters				Go		Advanced Search	→
	Microbiome Companies Per Regio	'n			_		
	Region: EU 101	•	Region: ROW	\rightarrow	Region: U: 152	5 & CA	\rightarrow
		/					

				times.com
	PER.			
	, _	5		
		Tag A		
		9,9		
ie			6.	
			C 30	<u>y.</u>
				J.
				, CO
	•			2
	Microbiome Drug Database			
	Login Welcome to Microbiome Drug Database	_		
	Pasword Normember Mo	© V ₀₁₄		

Who should subscribe to the Microbiome Drug Database and why?



Service Providers

(CROs, CDMOs, Sequencing companies, consultancies)



Microbiome Biotechs



Pharma & Investors



Business Development

Identify potential biotech parnters by matching relevant research programs to your expertise. By keeping an eye on the development stages, you can make contact at the right time through our LinkedIn integration tool or company e-mail.

Strategic Decision Making


Keep an up-to-date view on the microbiome drug landscape to help with IP decisions, benchmarking, current analytics to approach investors as well as identify potential collaborations and partnerships.

Scouting

Keep an up-to-date view on the microbiome pharmaceutical landscape, scout new investments, technologies and strategic partnerships as well as identify niches and trends. Gain access to our bi-annual market reports.

Use advanced search criteria and filters to focus on the companies








Search by:

Therapeutic Cluster

Search by each research program's Therapeutic Application, including Oncology, Gut-Brain Axis, Immune-Mediated Diseases, Dermatology, Metabolic Diseases and Infectious Diseases, as well as specific disease target.

Disease Targets


Information on the disease target of each research program. Search programs targeting specific diseases.



Carrow, Non-Grout C Disease, 3% Carcow, Prostates, 3% Long, 3%

Therapeutic Approach

Browse by Therapeutic Approach employed by each research program, including: Faecal Transplant, Defined Consortium, Single Strain, Postbiotics, Small molecules, GMO microorganisms, Bacteriophages and Microbiome-Based Diagnostics.



Search by:


Development Stage

Filter by the stage at which the research program is currently.

A useful tool for searching preclinical vs. clinical-stage companies.

clinicaltrials.gov Integration

View details of sponsors' clinical studies via **clinicaltrials.gov** integration tool.




Microbiome Drug Database

Geography

Find companies by geographic location.

Whereas over the majority of microbiome biotechs are based in the USA, Canada or Europe, a growing number of them are being founded in other geographical areas like China, South Korea and Israel.





Browse through almost 315+ companies and 1,350+ active research programs.

De Of Life Science and Technology Co., Ltd. → 4D Pharma PLC A-Mansia Biotech S.A. → Actym Actym Therapeutics, Inc.	÷
A-Monsia Actym	
	÷
☆ ADAPSYN Adapsyn Bioscience, Inc. → Obstruction of the proper arrow Adaptive Phage Therapeutics, Inc.	÷
Advaxis Immunothorapy	÷
Alleens Pharma Srl →	÷
ALPHABIOMICS AlphaBiomics Ltd. → Alveolus Bio, Inc.	÷



Every company has a separate page setting out company information, contact details, information on financing and detailed information on research program activity.

Micro Drug Da	obiome ^{stabase}		Home	Companies	Search	Users	Logos	Prof
	ompanies					A	2	Advanced Search \rightarrow
Company: Rebi	otix, Inc.							
		website:	: https://www.rebiotix.com	ป		Send Email		in LinkedIn
		M&A, Parent Company / Group: Ferring Holding SA Year Founded: 2011 Continent: United States and Canada				Country: United States of America (the) Partner: N/A Total Financing Raised: (€M) 42.72		
Research Prog	grams							
Programme	Application Cluster	Disease Targets	Development St	ago N	Aicrobiome App	roach	Partner	clinicaltrials.gov
RBX2660	Infectious diseases	C. difficile Infections	Market		FMT		N/A	
RBX7455	Infectious diseases	C. difficile Infections	Phase 1		FMT		N/A	



Contact us for a demo at nick@microbiometimes.com

Annual Subscription: €4950 (exc. VAT) per organisation



